Arcadia Biosciences receives Nasdaq delisting notice for bid price below $1.00

Arcadia Biosciences, Inc.

Nasdaq notice on Aug 4, 2026: RKDA failed minimum bid price ($1.00) for 30 consecutive business days (Jun 22–Aug 3).
180-day cure period until Feb 1, 2027; must close at $1.00+ for 10 consecutive business days to regain compliance.
Company may consider reverse stock split to cure deficiency; no immediate impact on listing or trading.
If not cured by Feb 1, 2027, may qualify for additional 180-day period if other listing standards are met.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.